Another great acquisition for CHM. Attracting the best by licensing the best.
Good to see chimeric starting to be recognised by industry commentators. This guy is an excellent resource to follow on LinkedIn with Cell and Gene industry news he is based in the UK. CHM gets a mention with the Jason Litten acquisition.
Ann: Cell therapy industry leader appointed Chief Medical Officer, page-11
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $21.93K | 1.168M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1519165 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1262067 | 4 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |